FIRST AMENDED AND RESTATED JOINT PRODUCT DEVELOPMENT AGREEMENTJoint Product Development Agreement • August 2nd, 2011 • Corgenix Medical Corp/Co • In vitro & in vivo diagnostic substances • Colorado
This First Amended and Restated Joint Product Development Agreement (“Agreement”) is made and entered into on this 28th day of July, 2011 (“Effective Date”), by and among Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), with its principal place of business at 12-12bis, rue Jean Jaurès, 92800 Puteaux, France, and Wescor, Inc., a Utah corporation (“Wescor”), with its principal place of business at 370 West 1700 South, Logan, Utah 84321. Each of Corgenix, Elitech and Wescor are sometimes referred to in this agreement individually as a “Party” and, collectively, as the “Parties.”
